Factbox-Race to launch weight-loss pills heats up as smaller players advance

Kailera’s late-stage China trial results show its oral obesity GLP-1 drug (HRS-7535), via an oral GLP-1 program, drove weight loss of up to 10.9% by week 44, while Structure Therapeutics reported up to 16.3% (39 lbs) after 44 weeks for aleniglipron. However, the competitive landscape is tightening as oral GLP-1 efficacy races ahead (e.g., Lilly’s orforglipron up to 12.4%) and at least one program missed top-end expectations (Viking VK2735 12.2% vs 15%). The article also notes U.S. pricing pressure and looming generics could shift the market outlook beyond the prior ~$150B decade forecast, with stock performance described as falling amid broader trading concerns.

Analysis

This is shifting the obesity complex from a pure efficacy race to a distribution-and-adherence race. In that regime, the winners are the companies that can monetize chronic therapy through payer leverage, manufacturing scale, and a primary-care sales machine; that structurally favors LLY and, to a lesser degree, NVO over single-asset or pre-commercial oral developers. The market may be underpricing how quickly oral differentiation compresses into a commodity once multiple compounds clear the same basic efficacy bar.

The second-order losers are the small/mid-cap names where the investment case depends on a long DCF bridge to 2027-2028 and repeated capital raises before late-stage de-risking. VKTX, GPCR, KLRA, and ASCLF are not trading like near-term commercial assets; they are financing- and execution-sensitive call options, so any disappointment in tolerability, dosing convenience, or liver/safety signals should hit multiples harder than raw weight-loss efficacy alone. Pfizer’s move reads more like strategic optionality than earnings accretion; preclinical assets do not change 12-month fundamentals.

Contrarian view: consensus is still assuming the obesity category keeps expanding linearly, but oral adoption could be self-limiting if persistence is worse than injections or if net pricing keeps eroding. That would keep the long-term market smaller than bulls expect and cap the re-rating of the entire basket. The key falsifier is real-world refill/persistence data over the next 1-2 quarters; if oral adherence is durable and payers tolerate broad access, the small-cap oral names deserve a higher multiple despite long timelines.

Key Decisions for Investors

• Long LLY / short XBI for 3-6 months: express the view that scale and payer power matter more than marginal efficacy; target low-to-mid single digit relative outperformance, stop if XBI regains leadership on a clean class readout.
• Short a basket of pre-commercial oral obesity names (VKTX, GPCR, KLRA, ASCLF) on strength over the next 1-3 months; risk/reward is favorable because dilution and phase-3 binary risk sit ahead of revenue.
• Avoid chasing PFE as a core obesity long; treat Metsera as optionality only. Revisit if upcoming preclinical/clinical disclosures show a clear tolerability or PK advantage that could justify premium valuation.
• Set an alert on LLY and NVO for evidence of net price erosion or slower script growth in the next earnings cycle; that is the main falsifier for the incumbent-winner thesis.